EGFR and neoplasm: Competing‐risks regression of time to death due to disease for high CD151, no epidermal growth factor receptor (EGFR) mutations group in early or advanced tumour, node, metastasis (TNM, American Joint Committee on Cancer [AJCC]) stage versus others in the Singaporean cohort.